John Eric Hug

Array ( [id] => 11407710 [patent_doc_number] => 09554995 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-31 [patent_title] => 'Nanoemulsions' [patent_app_type] => utility [patent_app_number] => 14/407819 [patent_app_country] => US [patent_app_date] => 2013-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 13 [patent_no_of_words] => 21297 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14407819 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9094863 [patent_doc_number] => 20130274174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-17 [patent_title] => 'THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 13/911990 [patent_app_country] => US [patent_app_date] => 2013-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 15131 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13911990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10265938 [patent_doc_number] => 20150150935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-04 [patent_title] => 'PERIPHERAL KAPPA RECEPTOR AGONISTS FOR REDUCING PAIN AND INFLAMMATION' [patent_app_type] => utility [patent_app_number] => 14/403535 [patent_app_country] => US [patent_app_date] => 2013-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 9918 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14403535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10662294 [patent_doc_number] => 20160008438 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-14 [patent_title] => 'Composition for Preventing or Treating Sepsis' [patent_app_type] => utility [patent_app_number] => 14/400293 [patent_app_country] => US [patent_app_date] => 2013-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 7343 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14400293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15538351 [patent_doc_number] => 10568934 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-25 [patent_title] => Method of treating AMD in patients refractory to anti-VEGF therapy [patent_app_type] => utility [patent_app_number] => 13/887555 [patent_app_country] => US [patent_app_date] => 2013-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 10471 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13887555 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11356323 [patent_doc_number] => 09532961 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-03 [patent_title] => 'Method and kit for administering γ-glutamyl-D-cysteine for the prevention of reperfusion injury following ischemic stroke' [patent_app_type] => utility [patent_app_number] => 13/868902 [patent_app_country] => US [patent_app_date] => 2013-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 22 [patent_no_of_words] => 12169 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13868902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11356323 [patent_doc_number] => 09532961 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-03 [patent_title] => 'Method and kit for administering γ-glutamyl-D-cysteine for the prevention of reperfusion injury following ischemic stroke' [patent_app_type] => utility [patent_app_number] => 13/868902 [patent_app_country] => US [patent_app_date] => 2013-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 22 [patent_no_of_words] => 12169 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13868902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12302652 [patent_doc_number] => 09937242 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-10 [patent_title] => Compositions and methods for inhibiting the activity of LAR family phosphatases [patent_app_type] => utility [patent_app_number] => 14/391589 [patent_app_country] => US [patent_app_date] => 2013-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 15 [patent_no_of_words] => 20895 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14391589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10007845 [patent_doc_number] => 09051349 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-09 [patent_title] => 'Larazotide acetate compositions' [patent_app_type] => utility [patent_app_number] => 13/832820 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 14 [patent_no_of_words] => 19206 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13832820 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9699398 [patent_doc_number] => 20140249083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-04 [patent_title] => 'FORMULATIONS OF GROWTH HORMONE RELEASING FACTOR (GRF) MOLECULES WITH IMPROVED STABILITY' [patent_app_type] => utility [patent_app_number] => 13/803712 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 18794 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13803712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9865283 [patent_doc_number] => 20150045302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-12 [patent_title] => 'PEPTIDES' [patent_app_type] => utility [patent_app_number] => 14/386415 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 22487 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14386415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8904771 [patent_doc_number] => 20130172274 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-04 [patent_title] => 'METHODS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS WITH ENHANCED PHARMACOLOGICAL PROPERTIES' [patent_app_type] => utility [patent_app_number] => 13/795955 [patent_app_country] => US [patent_app_date] => 2013-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 8037 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13795955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9858417 [patent_doc_number] => 20150038435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-05 [patent_title] => 'N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/380914 [patent_app_country] => US [patent_app_date] => 2013-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43134 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14380914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11224505 [patent_doc_number] => 09452215 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-27 [patent_title] => 'Bourvadin derivatives and therapeutic uses thereof' [patent_app_type] => utility [patent_app_number] => 14/380361 [patent_app_country] => US [patent_app_date] => 2013-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 45 [patent_no_of_words] => 25700 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14380361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9671681 [patent_doc_number] => 20140235544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-21 [patent_title] => 'DISEASE TREATMENT VIA ANTIMICROBIAL PEPTIDES OR THEIR INHIBITORS' [patent_app_type] => utility [patent_app_number] => 13/767890 [patent_app_country] => US [patent_app_date] => 2013-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 35231 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13767890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10000365 [patent_doc_number] => 09044438 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-02 [patent_title] => 'Disease treatment via antimicrobial peptides or their inhibitors' [patent_app_type] => utility [patent_app_number] => 13/759078 [patent_app_country] => US [patent_app_date] => 2013-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 24 [patent_no_of_words] => 35393 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13759078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9086529 [patent_doc_number] => 08557958 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2013-10-15 [patent_title] => 'Compositions and methods for treatment of diabetes' [patent_app_type] => utility [patent_app_number] => 13/757475 [patent_app_country] => US [patent_app_date] => 2013-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 21662 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13757475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10898111 [patent_doc_number] => 08921324 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-12-30 [patent_title] => 'Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides' [patent_app_type] => utility [patent_app_number] => 13/757148 [patent_app_country] => US [patent_app_date] => 2013-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 32859 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13757148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8842223 [patent_doc_number] => 20130137851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-30 [patent_title] => 'TARGETED DELIVERY OF ANTIMICROBIAL AGENTS' [patent_app_type] => utility [patent_app_number] => 13/757202 [patent_app_country] => US [patent_app_date] => 2013-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 14516 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13757202 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8866586 [patent_doc_number] => 20130150289 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-13 [patent_title] => 'Crystalline Peptide Epoxy Ketone Protease Inhibitors and the Synthesis of Amino Acid Keto-Epoxides' [patent_app_type] => utility [patent_app_number] => 13/757113 [patent_app_country] => US [patent_app_date] => 2013-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 32871 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13757113 [rel_patent_id] =>[rel_patent_doc_number] =>)